A recent study published in Ophthalmology has found that a combination of polihexanide (PHMB) and propamidine is a safe and effective treatment for the rare eye infection Acanthamoeba keratitis (AK). The study, conducted by John K.G. Dart and his team at Moorfields Eye Hospital in London, compared two treatment options for AK involving different concentrations of PHMB. The analysis included 127 patients.
The researchers discovered that both treatment options had a high medical cure rate within 12 months, with the adjusted rates being 86.6 percent for PHMB 0.02 percent + propamidine and 86.7 percent for PHMB 0.08 percent. These results met the noninferiority requirement for the higher concentration of PHMB. Secondary outcomes for both groups were also similar, with a median best-corrected visual acuity of 20/20 and an overall treatment failure rate of 13.4 percent, of which 6.3 percent required therapeutic keratoplasty. Importantly, no serious drug-related adverse events were reported.
Dart expressed his optimism about the findings, stating, “We hope that our new robust findings with polihexanide 0.08 percent will be a game changer for AK treatment, by improving access and the consistency of treatment, addressing currently unmet patient needs.”
It is worth noting that several authors involved in the study disclosed ties to pharmaceutical companies, including SIFI S.p.A., which sponsored and funded the trial.
For more information, you can access the abstract and full text of the study [here](https://www.aaojournal.org/article/S0161-6420(23)00710-8/fulltext).
Copyright © 2023 HealthDay. All rights reserved.